Scandinavian Real Heart

Realheart Receives Patent Approval in the US

Västerås, Sweden, June 17, 2025 – Scandinavian Real Heart AB (publ) announces today that the company has been granted patent approval by the United States Patent and Trademark Office (USPTO) concerning the core technology of Realheart® TAH. The same patent has previously been approved in the European Patent Office (EPO).

The newly approved patent (US patent no. 12318603 B2) covers the key technology of Realheart® TAH, the only artificial four-chamber heart that mimics the physiology of the natural human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. The structural design may provide important benefits, e.g., a reduced risk of stroke, bleeding, and anemia – common side effects seen with treatments using currently approved artificial heart devices.

The patent approval confers market protection for the device in the US until 2037.

Datum 2025-06-17, kl 08:30
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!